On Thursday, Zydus Lifesciences Ltd. announced that the US health regulatory has granted its generic version of the cancer treatment medication Cyclophosphamide capsules final approval. Zydus Lifesciences stated in a regulatory filing that the US Food and Drug Administration (USFDA) has approved Cyclophosphamide capsules in strengths of 25 mg and 50 mg.
It also stated that the medication will be produced in the group’s formulation manufacturing plant located in the Ahmedabad Special Economic Zone, India.
One chemotherapy drug that suppresses the proliferation of cancer cells is cyclophosphamide. According to the manufacturer, it treats leukaemia, lymphoma, myeloma, breast cancer, and ovarian cancer.
Zydus Lifesciences said that cyclophosphamide capsules, both 25 mg and 50 mg, achieved yearly sales of USD 6 million in the US, citing IQVIA MAT (moving annual total) statistics from October 2023.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
